Literature DB >> 10191288

Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice.

H Hosoai1, N R Webb, J M Glick, U J Tietge, M S Purdom, F C de Beer, D J Rader.   

Abstract

Plasma concentrations of high density lipoprotein (HDL) cholesterol and its major apolipoprotein (apo)A-I are significantly decreased in inflammatory states. Plasma levels of the serum amyloid A (SAA) protein increase markedly during the acute phase response and are elevated in many chronic inflammatory states. Because SAA is associated with HDL and has been shown to be capable of displacing apoA-I from HDL in vitro, it is believed that expression of SAA is the primary cause of the reduced HDL cholesterol and apoA-I in inflammatory states. In order to directly test this hypothesis, we constructed recombinant adenoviruses expressing the murine SAA and human SAA1 genes (the major acute phase SAA proteins in both species). These recombinant adenoviruses were injected intravenously into wild-type and human apoA-I transgenic mice and the effects of SAA expression on HDL cholesterol and apoA-I were compared with mice injected with a control adenovirus. Plasma levels of SAA were comparable to those seen in the acute phase response in mice and humans. However, despite high plasma levels of murine or human SAA, no significant changes in HDL cholesterol or apoA-I levels were observed. SAA was found associated with HDL but did not specifically alter the cholesterol or human apoA-I distribution among lipoproteins. In summary, high plasma levels of SAA in the absence of a generalized acute phase response did not result in reduction of HDL cholesterol or apoA-I in mice, suggesting that there are components of the acute phase response other than SAA expression that may directly influence HDL metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191288

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  23 in total

1.  Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity.

Authors:  Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke
Journal:  J Lipid Res       Date:  2015-05-20       Impact factor: 5.922

2.  Deficiency of Endogenous Acute-Phase Serum Amyloid A Protects apoE-/- Mice From Angiotensin II-Induced Abdominal Aortic Aneurysm Formation.

Authors:  Nancy R Webb; Maria C De Beer; Joanne M Wroblewski; Ailing Ji; William Bailey; Preetha Shridas; Richard J Charnigo; Victoria P Noffsinger; Jassir Witta; Deborah A Howatt; Anju Balakrishnan; Debra L Rateri; Alan Daugherty; Frederick C De Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-05       Impact factor: 8.311

Review 3.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

4.  Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease.

Authors:  Ashaunta Tumblin; Anitaben Tailor; Gerard T Hoehn; A Kyle Mack; Laurel Mendelsohn; Lita Freeman; Xiuli Xu; Alan T Remaley; Peter J Munson; Anthony F Suffredini; Gregory J Kato
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

5.  Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

6.  Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2.

Authors:  Rong L He; Jian Zhou; Crystal Z Hanson; Jia Chen; Ni Cheng; Richard D Ye
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

7.  Changes in plasma LDL and HDL composition in patients undergoing cardiac surgery.

Authors:  M Hacquebard; A Ducart; D Schmartz; W J Malaisse; Y A Carpentier
Journal:  Lipids       Date:  2007-10-03       Impact factor: 1.880

Review 8.  Serum amyloid A1: Structure, function and gene polymorphism.

Authors:  Lei Sun; Richard D Ye
Journal:  Gene       Date:  2016-03-03       Impact factor: 3.688

9.  Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2).

Authors:  Wijtske Annema; Niels Nijstad; Markus Tölle; Jan Freark de Boer; Ruben V C Buijs; Peter Heeringa; Markus van der Giet; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2010-01-08       Impact factor: 5.922

10.  Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner.

Authors:  Patricia G Wilson; Joel C Thompson; Nancy R Webb; Frederick C de Beer; Victoria L King; Lisa R Tannock
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.